Northern Trust Corp Has $30.67 Million Holdings in Ironwood Pharmaceuticals, Inc. (IRWD)

Northern Trust Corp grew its position in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 5.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,624,268 shares of the biotechnology company’s stock after purchasing an additional 88,464 shares during the period. Northern Trust Corp owned 1.09% of Ironwood Pharmaceuticals worth $30,667,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. Principal Financial Group Inc. boosted its stake in shares of Ironwood Pharmaceuticals by 0.3% during the 1st quarter. Principal Financial Group Inc. now owns 24,051 shares of the biotechnology company’s stock worth $410,000 after purchasing an additional 62 shares during the last quarter. Raymond James Financial Services Advisors Inc. boosted its position in shares of Ironwood Pharmaceuticals by 8.0% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 12,161 shares of the biotechnology company’s stock worth $207,000 after acquiring an additional 898 shares during the last quarter. Aperio Group LLC boosted its position in shares of Ironwood Pharmaceuticals by 11.9% in the second quarter. Aperio Group LLC now owns 13,213 shares of the biotechnology company’s stock worth $249,000 after acquiring an additional 1,410 shares during the last quarter. Amalgamated Bank boosted its position in shares of Ironwood Pharmaceuticals by 9.0% in the second quarter. Amalgamated Bank now owns 17,280 shares of the biotechnology company’s stock worth $326,000 after acquiring an additional 1,421 shares during the last quarter. Finally, Legal & General Group Plc boosted its position in shares of Ironwood Pharmaceuticals by 5.0% in the second quarter. Legal & General Group Plc now owns 47,773 shares of the biotechnology company’s stock worth $900,000 after acquiring an additional 2,265 shares during the last quarter. 97.16% of the stock is currently owned by institutional investors.

Several equities research analysts recently issued reports on IRWD shares. BidaskClub raised shares of Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Mizuho raised their target price on shares of Ironwood Pharmaceuticals from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Tuesday, July 4th. Zacks Investment Research raised shares of Ironwood Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, July 17th. J P Morgan Chase & Co reissued a “neutral” rating and issued a $19.00 target price (down from $20.00) on shares of Ironwood Pharmaceuticals in a research report on Friday, July 21st. Finally, Wood & Company cut shares of Ironwood Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research report on Friday, July 21st. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $18.29.

Ironwood Pharmaceuticals, Inc. (IRWD) opened at 15.40 on Wednesday. Ironwood Pharmaceuticals, Inc. has a 12-month low of $12.48 and a 12-month high of $19.94. The stock’s market cap is $2.30 billion. The company has a 50-day moving average of $15.92 and a 200 day moving average of $16.86.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.28) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.05). Ironwood Pharmaceuticals had a negative net margin of 52.97% and a negative return on equity of 333.83%. The business had revenue of $65.10 million for the quarter, compared to analysts’ expectations of $70.00 million. During the same period last year, the firm earned ($0.16) EPS. The company’s revenue was up 19.7% compared to the same quarter last year. Equities analysts anticipate that Ironwood Pharmaceuticals, Inc. will post ($1.11) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This report was reported by Markets Daily and is the sole property of of Markets Daily. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.themarketsdaily.com/2017/10/18/northern-trust-corp-has-30-67-million-holdings-in-ironwood-pharmaceuticals-inc-irwd.html.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.

Want to see what other hedge funds are holding IRWD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD).

Institutional Ownership by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply